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Summary
Background Many international guidelines on the prevention of venous thromboembolism recommend targeting 
heparin treatment at patients with stroke who have a high risk of venous thrombotic events or a low risk of 
haemorrhagic events. We sought to identify reliable methods to target anticoagulant treatment and so improve the 
chance of avoiding death or dependence after stroke.
Methods We obtained individual patient data from the ﬁ ve largest randomised controlled trials in acute ischaemic 
stroke that compared heparins (unfractionated heparin, heparinoids, or low-molecular-weight heparin) with aspirin 
or placebo. We developed and evaluated statistical models for the prediction of thrombotic events (myocardial 
infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorrhagic events (symptomatic intracranial 
or signiﬁ cant extracranial) in the ﬁ rst 14 days after stroke. We calculated the absolute risk diﬀ erence for the outcome 
“dead or dependent” in patients grouped by quartiles of predicted risk of thrombotic and haemorrhagic events with 
random eﬀ ect meta-analysis.
Findings Patients with ischaemic stroke who were of advanced age, had increased neurological impairment, or had 
atrial ﬁ brillation had a high risk of both thrombotic and haemorrhagic events after stroke. Additionally, patients with 
CT-visible evidence of recent cerebral ischaemia were at increased risk of thrombotic events. In evaluation datasets, 
the area under a receiver operating curve for prediction models for thrombotic events was 0·63 (95% CI 0·59–0·67) 
and for haemorrhagic events was 0·60 (0·55–0·64). We found no evidence that the net beneﬁ t from heparins 
increased with either increasing risk of thrombotic events or decreasing risk of haemorrhagic events.
Interpretation There was no evidence that patients with ischaemic stroke who were at higher risk of thrombotic 
events or lower risk of haemorrhagic events beneﬁ ted from heparins. We were therefore unable to deﬁ ne a targeted 
approach to select the patients who would beneﬁ t from treatment with early anticoagulant therapy. We recommend 
that guidelines for routine or selective use of heparin in stroke should be revised.
Funding MRC. 
Introduction
Every year, ischaemic stroke kills 2·9 million people and 
leads to 3·4 million years lived with disability 
worldwide.1,2 Short-term stroke recovery is often 
complicated by venous thromboembolism (1–5%) and 
recurrent stroke (1–20%).3,4 Prevention of the arterial 
and venous thrombo embolic complications of stroke 
could contribute to reduction of the burden of stroke-
related disabilities.
Although heparins (unfractionated heparin, low-
molecular-weight heparin, and heparinoids) can reduce 
the risk of recurrent ischaemic stroke, deep vein 
thrombosis, and pulmonary embolism, they also 
increase the risk of symptomatic intracranial and 
extracranial haemorrhage.5 In stroke, the beneﬁ ts are 
exactly oﬀ set by the harms, and hence in systematic 
reviews of grouped data from randomised controlled 
trials of subcutaneous heparins, there was no net 
observable eﬀ ect of anticoagulants on death or disability 
measured several months after stroke (even in selected 
subtypes).6–8 
However, some clinicians still use heparin or low-
molecular-weight heparin to prevent early recurrent 
stroke in patients who are felt to be at particularly high 
risk.9–13 In the third International Stroke Trial (IST-3),14 
24% of patients were treated with low-dose heparin and 
8% were fully anticoagulated with high-dose heparin or 
warfarin in the ﬁ rst week after stroke, consistent with 
recent registry data from the USA, Germany, France, 
and Australia.9,14–18 Additionally, regimens of low-dose 
unfractionated heparin and low-molecular-weight 
heparin are commonly prescribed for the prevention of 
deep vein thrombosis and pulmonary embolism in 
patients with stroke.19 National UK and other country 
guidelines recommend prophylactic doses of heparins 
for patients with stroke who are deemed at high risk of 
Lancet Neurol 2013; 12: 539–45
Published Online
May 2, 2013
http://dx.doi.org/10.1016/
S1474-4422(13)70079-6
See Comment page 526
Division of Clinical 
Neurosciences, University of 
Edinburgh, Bramwell Dott 
Building, Western General 
Hospital, Edinburgh, UK 
(W N Whiteley PhD, 
M Dennis MD, 
P A G Sandercock MD); 
Department of Neurology, 
University of Iowa, Iowa City, 
USA (H P Adams Jr MD); Division 
of Stroke, University of 
Nottingham, Clinical Sciences 
Building, City Hospital Campus, 
Nottingham, UK 
(P M W Bath FRCP); Oslo 
University Hospital, 
Department of Haematology, 
and University of Oslo, 
Institute of Clinical Medicine, 
Oslo, Norway (E Berge MD, 
P M Sandset MD); Centre for 
Population Health Sciences, 
University of Edinburgh, 
Edinburgh, UK 
(G D Murray PhD); Division of 
Neurology, Chinese University 
of Hong Kong, Prince of Wales 
Hospital, Shatin, New 
Territories, Hong Kong, China 
(K-S L Wong MD)
Correspondence to:
Dr William Whiteley
Division of Clinical 
Neurosciences, University of 
Edinburgh, Western General 
Hospital, Edinburgh EH4 2XU, 
UK
william.whiteley@ed.ac.uk
Articles
540 www.thelancet.com/neurology   Vol 12   June 2013
venous thromboembolism20 or those at low risk of 
bleeding,21 although this stratiﬁ ed approach had not 
previously been studied.
We aimed to test the hypothesis that a policy of using 
clinical data to target heparins in patients with ischaemic 
stroke who have a high risk of venous or arterial 
thromboembolism, and avoiding heparins in patients 
with a high risk of bleeding, leads to overall better 
outcomes. Such a hypothesis might also be of relevance 
to the use of thromboprophylaxis in other groups of 
medical patients. We therefore undertook a meta-analysis 
of individual patient data from the ﬁ ve largest randomised 
trials of unfractionated heparin, heparinoids, and low-
molecular-weight heparin in acute ischaemic stroke.22
Methods
Procedures
We obtained individual patient data from the ﬁ ve largest 
randomised controlled trials of heparins versus either 
aspirin or placebo in acute ischaemic stroke that 
measured post-stroke dependence: IST;23,24 the Trial of 
ORG 10172 in Acute Stroke Treatment (TOAST);25 the 
Tinzaparin in Acute Ischaemic Stroke Trial (TAIST);26 the 
Heparin in Acute Embolic Stroke Trial (HAEST);27 and 
Fraxiparin in Stroke Study for the treatment of ischemic 
stroke (FISS-tris).28 We included only those patients from 
IST for whom the baseline diagnosis was probable or 
deﬁ nite ischaemic stroke. We identiﬁ ed the trials by use 
of the latest Cochrane review of anticoagulants in acute 
stroke.6 We did not obtain individual patient data from 
22 other trials of heparins because they were small (fewer 
than 100 patients), they were not clearly randomised, or 
their data were not readily available. 
We obtained the following baseline variables from 
each trial (using the trial deﬁ nitions): age, sex, delay 
from stroke onset to randomisation, level of 
consciousness, facial weakness, arm weakness, leg 
weakness, presence of atrial ﬁ brillation at 
randomisation, systolic blood pressure at randomisation, 
and history of myocardial infarction, stroke, or diabetes 
mellitus. We used the National Institutes of Health 
stroke scale (NIHSS) as a measure of initial neurological 
impairment due to stroke. Where the Scandinavian 
stroke scale (SSS) was measured, we converted it to the 
NIHSS with a previously developed conversion 
algorithm.29 IST recorded neither the NIHSS nor the 
SSS, so we used an algorithm developed in the IST-3 
dataset to convert data for eight simple questions of 
neurological deﬁ cit into an NIHSS score.14 Three trials 
recorded the Oxfordshire Community Stroke Project 
(OCSP) classiﬁ cation at baseline.30 For the remaining 
two trials we converted symptoms recorded in 
components of the NIHSS scale into an OCSP 
classiﬁ cation with a previously developed algorithm.31
We deﬁ ned two early outcome events: a composite of 
thrombotic events within 14 days (any fatal or non-fatal 
pulmonary embolism, deep vein thrombosis, myocardial 
infarction, or recurrent ischaemic stroke [not stroke 
extension alone] as deﬁ ned by each trial, up to and 
including 14 days after randomisation); and a composite 
of haemorrhagic events within 14 days (any recorded fatal 
or non-fatal intracranial haemorrhage, or extra cranial 
haemorrhages that led to death, transfusion, or surgery, 
up to and including 14 days post randomisation). We 
deﬁ ned the state of being dead or dependent at ﬁ nal 
follow-up as: in FISS-tris and TAIST,  a modiﬁ ed Rankin 
scale score of 3–6; in IST and HAEST, being either dead 
or responding yes to the question “did you need help 
from another person to perform everyday activities 
within the last 2 weeks?”; or, in TOAST, a Glasgow 
outcome scale of 1–3 (dead to severely dependent). Some 
studies measured death or dependence at 3 months and 
some at 6 months (table 1). We made no speciﬁ c 
allowance for diﬀ ering follow-up times because we made 
within-study comparisons of the proportion of patients 
dead or dependent at the end of follow-up.
Predictive models
We searched the medical literature systematically for 
validated predictive models of short-term haemorrhagic or 
IST TOAST FISS-tris HAEST TAIST
Agent and dose UFH, 12 500 IU 
subcutaneously or 5000 IU 
subcutaneously twice a day
Heparinoid (danaparoid), 
intravenously adjusted to 
factor Xa activity
LMWH (nadroparin 
calcium), 3800 anti-factor 
Xa IU subcutaneously  
twice a day
LMWH (dalteparin), 
100 IU/kg subcutaneously 
twice a day
LMWH (tinzaparin), 175 anti-Xa IU/kg 
or 100 anti-Xa IU/kg subcutaneous 
daily
Length of treatment 14 days 7 days 10 days 14 days 10 days
Control Aspirin 300mg or avoid 
aspirin
Placebo Aspirin 160 mg Aspirin 160 mg Aspirin 300 mg
Randomised 2×2 factorial 1:1 1:1 1:1 1:1:1
Deﬁ nition of death or dependence IST scale Glasgow outcome scale Modiﬁ ed Rankin scale IST scale Modiﬁ ed Rankin scale
Time of follow-up for death or 
dependence
6 months 3 months 6 months 3 months 6 months
IST=International Stroke Trial. TOAST=Trial of ORG 10172 in Acute Stroke Treatment. FISS-tris=Fraxiparin in Stroke Study for the treatment of ischemic stroke. HAEST=Heparin in Acute Embolic Stroke Trial.  
TAIST= Tinzaparin in Acute Ischaemic Stroke Trial. IU=international units. LMWH=low-molecular-weight heparin. UFH=unfractionated heparin.
Table 1: Characteristics of included trials
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all thrombotic events after a stroke of moderate to major 
severity, but found none. We therefore developed and 
validated predictive models for “all haemorrhagic events” 
and “all thrombotic events” with the available data.
We ﬁ rst measured the associations between baseline 
clinical variables and either all thrombotic or all 
haemorrhagic events in each trial with univariate logistic 
regression. We calculated a summary estimate of these 
odds ratios and their 95% CI with random eﬀ ects meta-
analysis, and calculated an I² statistic as a measure of 
heterogeneity between studies. We developed predictive 
models in the large IST dataset with variables that were 
plausibly and signiﬁ cantly associated with thrombotic or 
haemorrhagic events.
As the best test of the external validity of prognostic 
models is to test them in diﬀ erent datasets, we used the 
TAIST, TOAST, FISS-tris, and HAEST trials (the test 
dataset) for evaluation rather than a random split of the 
data.32 We measured discrimination in the test dataset by 
calculating the area under a receiver operating 
characteristic curve (AUROCC) and its 95% CI. One 
interpretation of the AUROCC is the proportion of 
randomly selected pairs of patients with and without an 
event, in which the patient with an event has a higher 
predicted risk of an event than the patient without an 
event. An AUROCC of 0·5 indicates no better 
discrimination than chance, and an AUROCC of 
1 indicates perfect discrimination. We measured 
calibration by plotting the predicted versus observed 
risks of events per quintile of predicted risk, and 
calculating the Hosmer Lemeshow χ² statistic, where 
2P>0·05 is one measure of a well calibrated model.
To measure the eﬀ ect of missing baseline variables 
on the strength of associations in the ﬁ nal multivariate 
model, we repeated the analysis with ten imputations 
of missing variables, using complete baseline variables 
as predictors of missing values with logistic regression 
equations.33 We also developed a model containing 
those available variables that were recommended in 
recent UK National Institute of Health and Care 
Excellence (NICE) guidelines21 to predict venous 
thromb oembolism in patients admitted to hospital: age 
over 60 years, presence of leg weakness, and presence 
of comorbidities. 
Statistical analysis
To establish whether the predicted risk of thrombotic or 
haemorrhagic events was associated with the response 
to heparins (measured by the proportion of patients 
dead or dependent at ﬁ nal follow-up), we divided the 
population of each of the ﬁ ve trials into sixteen groups, 
deﬁ ned by quartiles of predicted risk of thrombotic 
events and quartiles of predicted risk of haemorrhagic 
events. For each group in each trial, we calculated the 
excess risk of death or disability in patients allocated to 
heparins compared with patients allocated to aspirin or 
placebo in each trial (intention to treat), and then used 
random eﬀ ects meta-analyses to pool the risk diﬀ erences 
from each trial in a summary estimate. This ensures 
that treated and untreated patients are compared within 
and not between trials, which maintains the balance 
achieved by randomisation as far as is possible. We 
repeated the analysis comparing low-dose heparins to 
placebo or aspirin, and high-dose heparins to placebo or 
aspirin. Because dichotomous outcomes are not as 
sensitive to small eﬀ ects as a more statistically eﬃ  cient 
ordinal approach, we also analysed disability and death 
on a common four-point disability scale with ordinal 
logistic regression.34 We tested the statistical signiﬁ cance 
of a multiplicative interaction between [(predicted risk 
of thrombosis) – (predicted risk of haemorrhage)] and 
treatment with heparins. We used Stata 11 for the 
analysis.  
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
For the statistical analysis plan 
see http://www.dcn.ed.ac.uk/
dcn/documents/proﬁ le_
protocols/whiteley_p3.pdf
IST (N=18836) TOAST (N=1281) FISS-tris N=603) HAEST (N=449) TAIST (N=1486) Total (N=22655)
Deep venous thrombosis 21 (0·1%) 12 (0·9%) 3 (0·5%) 5 (1·1%) 16 (1·1%) 57 (0·3%)
Pulmonary embolism 126 (0·7%) 6 (0·5%) 0 (0·0%) 1 (0·2%) 11 (0·7%) 144 (0·6%)
Ischaemic stroke 646* (3·4%) 62 (4·8%) 31 (5·1%) 36 (8·0%) 42 (2·8%) 817 (3·6%)
Myocardial infarction 362 (1·9%) 17 (1·3%) ·· 4 (0·9%) ·· 383 (1·7%)
Any thrombotic events 1141 (6·1%) 36 (2·8%) 16 (2·7%) 45 (10·0%) 64 (4·3%) 1302 (5·7%)
Signiﬁ cant intracranial haemorrhage 127 (0·7%) 21 (1·6%) 15 (2·5%) 10 (2·2%) 11 (0·7%) 184 (0·8%)
Major extracranial haemorrhage 163 (0·9%) 31 (2·4%) 2 (0·3%) 3 (0·7%) 8 (0·5%) 207 (0·9%)
Any haemorrhagic event 285 (1·5%) 43 (3·4%) 14 (2·3%) 13 (2·9%) 19 (1·3%) 374 (1·7%)
Dead or dependent† 11 654 (61·9%) 294 (23·0%) 157 (26·0%) 294 (65·5%) 831 (55·9%) 13 230 (58·4%)
Data are n (%). *Includes patients where recurrent stroke subtype was uncertain. †143 (<1%) of patients had missing dead or dependent status at ﬁ nal follow-up. Each 
number signiﬁ es an individual with a haemorrhagic or a thrombotic event. 27 individuals had both a haemorrhagic and a thrombotic event. Events are uniformly counted 
from 14 days after randomisation, hence minor diﬀ erences from trial publication in number of events.
Table 2: Thrombotic and haemorrhagic events within 14 days and death or dependence at ﬁ nal follow-up
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Results
We obtained data for 22 655 patients with ischaemic 
stroke who were randomised to either an anticoagulant 
regimen (unfractionated heparin, low-molecular-weight 
heparin, or heparinoid) or to aspirin or placebo from the 
IST, TOAST, FISS-tris, HAEST, and TAIST studies. The 
key design features of each trial are summarised in 
table 1. The clinical features of patients at baseline in 
each study are summarised in the appendix. By 14 days 
after randomisation, about 1 in 20 patients had had a 
thrombotic event (1302 [5·7%]; table 2), most of which 
were recurrent ischaemic strokes (817 [3·6%]). Signiﬁ cant 
haemorrhagic events were recorded about a third as 
often as thrombotic events by 14 days after randomisation 
(374 [1·7%]; table 2), with similar numbers of extracranial 
and intracranial haemorrhages (207 [0·9%] and 
184 [0·8%], respectively). About two-thirds of patients 
were dead or dependent at the time of last follow-up 
(13 230 [58·4%]), although the proportion was lower in 
the TOAST and FISS-tris trials (table 2). Patients 
randomly assigned to a heparin regimen had a 1·6% 
absolute increase in the risk of haemorrhagic events and 
a 1·4% reduction in the risk of thrombotic events 
compared with those assigned to aspirin or placebo. For 
low-dose heparin versus aspirin or placebo, the 
proportions were a 0·5% increase and a 1·4% decrease. 
Patients who had a haemorrhagic or thrombotic event 
within 2 weeks of stroke had a high risk of death or 
dependence: 82% of patients who had a haemorrhagic 
event and 88% of patients who had a thrombotic event 
were dead or dependent at ﬁ nal follow-up.
In univariate analysis, four factors were signiﬁ cantly 
and consistently associated across trials with the risk of 
thrombotic events after stroke: increasing age, presence 
of atrial ﬁ brillation, a CT-visible infarction, and an 
increasing NIHSS score (ﬁ gure 1). A prediction model 
constructed with these four variables (table 3) using 
data from the IST dataset discriminated moderately well 
between those patients who did have a thrombotic event 
by 14 days post-stroke and those who did not, both in 
the development dataset (AUROCC 0·60, 95% CI 
0·58–0·62) and in the test dataset (0·63, 0·59–0·67). 
There was no improvement in model ﬁ t with non-linear 
transformations of the NIHSS score, age, delay from 
stroke, or systolic blood pressure. Multiple imputation 
of missing variables made little diﬀ erence to the 
magnitude or directions of the association seen in the 
model created in the development dataset. In the test 
dataset, there was a positive gradient of thrombotic 
events by quintiles of predicted risk of thrombotic 
events (table 4), from a 2·0% risk in the lowest quintile 
to 7·0% in the highest quintile. 
Models to predict symptomatic venous thrombo-
embolism alone discriminated moderately well between 
patients who developed venous thromboembolism and 
those who did not in the test dataset when based on 
variables that predicted all thrombotic events (AUROCC 
0·66, 95% CI 0·59–0·73), but not when based on 
available variables suggested in the NICE guidelines: age 
older than 60 years, presence of leg weakness, and 
presence of comorbidities (0·49, 0·46–0·52).
Increasing age, increasing NIHSS score, and the 
presence of atrial ﬁ brillation were associated with an 
increased risk of any haemorrhagic event (ﬁ gure 2). A 
prediction model constructed from these three variables 
(table 3) discriminated only moderately between those 
patients who developed a haemorrhagic event within 
14 days in the IST development dataset (AUROCC 0·61, 
95% CI 0·58–0·64) with a similar performance in the 
test dataset (0·60, 0·55–0·64). In the test dataset, there 
was a moderate gradient of increased absolute risk of 
haemorrhagic events by quintiles of predicted risk of 
haemorrhage from the lowest (1·6%) to the highest 
(4·6%) quintile (table 4).
Patients in each trial were divided into sixteen groups, 
deﬁ ned by quartiles of risk of all haemorrhagic events 
and quartiles of risks of all thrombotic events (table 5). 
Odds ratio (95% CI) p
Prediction model for all thrombotic events
Age (per year) 1·02 (1·02–1·03) <0·0001
Presence of atrial ﬁ brillation 1·24 (1·02–1·51) 0·007
Presence of CT evidence of recent cerebral ischaemia 1·18 (1·03–1·35) 0·014
NIHSS (per point) 1·04 (1·02–1·05) <0·0001
Prediction model for all haemorrhagic events
Age (per year) 1·01 (1·00–1·02) 0·04
Presence of atrial ﬁ brillation 1·09 (0·78–1·50) 0·60
NIHSS (per point) 1·06 (1·04–1·09) <0·0001
NIHSS=National Institutes of Health stroke scale. 
T able 3: Prediction models for thrombotic and haemorrhagic events developed in the IST dataset
n/N 2P I2OR (95% CI)Variable
Age (per decade)
Male sex
History of myocardial infarction
History of stroke
History of diabetes mellitus
Prior antiplatelet agents
Atrial fibrillation
NIHSS (per point)
Weight (per kg)
Randomisation blood pressure (per mm Hg)
Stroke to randomisation delay (per hour)
Presence of CT visible acute infarct
Total anterior stroke syndrome (vs others)
 1302/22 655
 1302/22 655
 160/3780
 159/3787
 97/2319
 1301/22 625
 1248/20 453
 1229/21  740
 156/3737
 1301/22 654
 1300/22 613
 1301/22 565
 1300/22 594
 1·24 (1·17–1·31)
 0·91 (0·75–1·10)
 0·87 (0·48–1·59)
 0·91 (0·56–1·48)
 0·69 (0·40–1·19)
 1·11 (0·98–1·20)
 1·50 (1·30–1·73)
 1·04 (1·02–1·06)
 0·99 (0·98–1·01)
 1·00 (1·00–1·01)
 1·00 (0·99–1·01)
 1·26 (1·12–1·42)
 1·52 (1·06–2·19)
 <0·001
 0·29
 0·65
 0·70
 0·18
 0·11
 <0·001
 0·001
 0·52
 0·39
 0·57
 <0·001
 0·02
0%
14%
44%
18%
0%
0%
0%
27%
59%
69%
15%
0%
57%
1·00·1 10·0
Odds ratio
Figure 1: Association of baseline variables with thrombotic events—myocardial infarction, recurrent 
ischaemic stroke, deep vein thrombosis, and pulmonary embolism 
Each square represents the point estimate from a random eﬀ ects meta-analysis across trials, and the horizontal 
line the 95% CI. N=number of patients. n=number of events in each meta-analysis. NIHSS=National Institutes of 
Health stroke scale. 
See Online for appendix
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We found that no group had a statistically signiﬁ cant 
beneﬁ t of heparins over aspirin or placebo for the 
prevention of death or disability at the time of last follow-
up. In none of the 16 groups was there evidence of 
signiﬁ cant heterogeneity between the risk diﬀ erences 
from the diﬀ erent trials. There was no visible pattern or 
trend of increasing beneﬁ t or harm across the groups. 
The results were similar when examining patients 
from IST alone; when examining patients from the 
HAEST, TAIST, TOAST, and FISS-tris trials together; 
when comparing patients randomly assigned to low-dose 
heparins with those randomised to aspirin or placebo; 
when comparing patients randomised to high-dose 
heparins with those randomised to aspirin or placebo; or 
where death at ﬁ nal follow-up was the outcome of 
interest. The term [(predicted thrombosis−predicted risk 
of haemorrhage) × heparin] was not signiﬁ cant in an 
ordinal logistic regression model (p=0·43).
Discussion
We have not been able to deﬁ ne a strategy that can reliably 
select the patients with ischaemic stroke who are most 
likely to beneﬁ t and least likely to be harmed by early 
heparin therapy. This stratiﬁ ed analysis of individual 
patient data from the ﬁ ve largest trials of heparins in acute 
stroke therefore provides no support for targeting the use 
of heparin, heparinoids, or low-molecular-weight heparin 
after stroke for the prevention of thrombotic events to 
reduce post-stroke death or disability using risk models 
based on simple clinical variables (including those 
proposed by NICE). 
Higher age, greater stroke severity, and the presence of 
atrial ﬁ brillation were associated with an increased risk 
of both thrombotic and haemorrhagic events. Therefore, 
patients at a higher predicted risk of thrombotic events 
were also at a higher risk of haemorrhagic events, and no 
single variable discriminated reliably between the risk of 
thrombosis and haemorrhage. 
This study has several limitations. The models that we 
produced were only moderately predictive of recurrent 
thrombotic or haemorrhagic events. Many prognostic 
models developed in patients with stroke have only poor 
to moderate predictive performance: for example, 
prediction models of bleeding (AUROCC 0·67),35 
recurrent stroke (0·61–0·68),36 and deep vein thrombosis 
(0·57).22 The accuracy of the models developed in our 
analysis was similar. However, unlike observational 
cohorts, the assessment of the eﬀ ect of heparins was 
unbiased because they were randomly allocated. Our 
predictive models might have been improved if we had 
been able to test important and plausible predictive 
variables that were missing in this dataset, such as renal 
failure, history of a previous venous thrombosis, or 
gastrointestinal haemorrhage. However, these events are 
fairly infrequent in clinical stroke practice. Because most 
thrombotic and haemorrhagic events occur in people 
without these risk factors, the addition of these variables 
is unlikely to have materially improved the performance 
and accuracy of predictive models.22 
Variables were deﬁ ned and obtained in diﬀ erent ways 
in diﬀ erent trials, which could have added random error 
to each of the variables (particularly measures of stroke 
severity). We used data from large randomised trials in 
which the primary focus was the collection of data for 
death or dependence at end of follow-up, rather than the 
collection of data on recurrent events or venous 
thromboembolism. Some important events were 
probably missed, which might have limited the 
discriminative performance of the predictive models. 
N Number of events (%)
Quintile of predicted risk of thrombotic event*
1 749 15 (2·0%)
2 744 23 (3·1%)
3 745 29 (3·9%)
4 746 41 (5·5%)
5 745 52 (7·0%)
Total 3729 160 (4·3%)
Quintile of predicted risk of haemorrhagic event†
1 763 12 (1·6%)
2 763 13 (1·7%)
3 764 18 (2·4%)
4 762 11 (1·4%)
5 763 35 (4·6%)
Total 3815 89 (2·3%)
N=number of patients. *Hosmer Lemeshow χ2=3·2, p=0·35. †Hosmer Lemeshow 
χ2=4·2, p=0·23.
T able 4: Number of thrombotic and haemorrhagic events by quintiles of 
predicted risk of event in evaluation datasets (TAIST, TOAST, FISS-tris, 
HAEST)
n/N 2P I2OR (95% CI)Variable
Age (per decade)
Male sex
History of myocardial infarction
History of stroke
History of diabetes mellitus
Prior antiplatelet agents
Atrial fibrillation
NIHSS (per point)
Weight (per kg)
Randomisation blood pressure (per mm Hg)
Stroke to randomisation delay (per hour)
Presence of CT visible acute infarct
Total anterior stroke syndrome (vs others)
 374/22 655
 374/22 655
 88/3692
 87/3787
 69/2319
 374/22 625
 358/21 701
 354/21  740
 89/3737
 374/22 645
 372/22 613
 373/22 565
 374/22 220
 1·16 (1·05–1·27)
 0·95 (0·78–1·17)
 1·15 (0·70–1·91)
 1·21 (0·64–2·29)
 0·67 (0·26–1·70)
 0·84 (0·65–1·08)
 1·34 (1·03–1·76)
 1·09 (1·04–1·14)
 1·00 (0·98–1·02)
 1·00 (1·00–1·01)
 1·00 (0·98–1·01)
 1·20 (0·79–1·82)
 1·90 (1·27–2·85)
 0·003
 0·65
 0·57
 0·55
 0·40
 0·17
 0·03
 <0·001
 0·83
 0·44
 0·61
 0·29
 0·002
0%
0%
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18%
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0%
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41%
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Figure 2: Association of baseline variables with haemorrhagic events (intracranial or extracranial 
haemorrhage) 
Each square represents the point estimate from a random eﬀ ects meta-analysis across trials, and the horizontal 
line the 95% CI. N=number of patients, n=number of events in each meta-analysis.
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Despite this, the proportion of patients with symptomatic 
events was within the bounds of those recorded by 
contemporaneous studies where the primary focus was 
the proportion of patients with short term post stroke 
complications.37 We identiﬁ ed trials found in a recent 
Cochrane systematic review,6 rather than updating the 
search; however, we believe that we are unlikely to have 
missed any large trials of heparins in acute stroke.
This analysis provides no support for the guideline 
recommendations and common clinical practice of 
individualised risk assessment of haemorrhagic or 
thrombotic events in patients with ischaemic stroke when 
making a decision whether to prescribe a heparin. To 
support such a practice, the analysis would need to show 
that prediction of early risk could be validated against the 
observed risk of thrombotic and haemorrhagic events, 
and that those patients who were at high predicted risk of 
further thrombotic events and low risk of haemorrhagic 
events were less likely to be dead or dependent after 
treatment with a heparin. Because we have analysed most 
of the available randomised evidence for patients with 
stroke, further large-scale observational data would be 
necessary to develop better predictive models, and more 
randomised trials of heparins would be needed to test 
whether the use of these models improved the eﬀ ect of a 
heparin on death and disability. Most of the prediction 
power of statistical models to predict early recurrent 
thrombotic and haemorrhagic events would still probably 
be determined by age and severity of symptoms, so 
additional factors (not correlated with age or symptom 
severity) would need to be identiﬁ ed. Candidate variables 
for the prediction of haemorrhage with heparin include 
brain microbleeds, renal impairment, a history of 
haemorrhagic events, or more detailed analysis of brain 
imaging ﬁ ndings; for the prediction of thrombotic events, 
variables include a history of venous thrombo embolism, 
an inherited thrombophilia, or cancer. 
Guidelines from the American College of Physicians38 
and NICE21 recommend an individualised assessment of 
risk of venous thromboembolism and the risk of 
haemorrhage before initiating a heparin in patients with 
stroke. Several potential individual risk predictors are 
given in both guidelines, although the discriminative 
performance of these factors was not stated. Both of these 
guidelines gave their recommendations by summing the 
beneﬁ t of treatment in terms of number of thrombotic 
events and the harms in terms of numbers of 
haemorrhagic events. Their analysis assumes that equal 
weight can be placed on non-fatal thrombotic and 
haemorrhagic events, which can be challenged because 
non-fatal pulmonary embolism is usually of less clinical 
signiﬁ cance than non-fatal intracranial haemorrhage.5 By 
using the primary outcome of the stroke studies—a 
global measure of dependency—we have not needed to 
make any assumption as to the weighting to be placed on 
haemorrhagic or thrombotic events. On our dependency 
scale, there was no evidence of beneﬁ t of heparins after 
ischaemic stroke in any risk group. 
Heparin, heparinoid, or low-molecular-weight heparin 
treatment did not reduce the risk of death or dependency 
in patients with ischaemic stroke who have a higher risk 
of thrombotic events or a lower risk of haemorrhagic 
events, either because there was no diﬀ erence, or because 
our models were only moderately predictive of events. In 
view of the lack of evidence for heparin prophylaxis in 
reducing mortality in other categories of high-risk 
medical patients, and in stroke, these data suggest 
current guideline recommendations for routine or 
selective use of heparin in stroke (and perhaps other 
patients) should be revised.
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